The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious disease, is pleased to welcome Joy Taylor to its Board of Trustees. Taylor is CEO of EastEdge Consulting Services, a Pennsylvania-based management consulting firm focused on organizational and operational improvement.
Scientists have long used community advisory boards to engage communities and provide feedback on studies, but this model has limitations. Now, Wistar Institute researchers are sharing how a more inclusive model for community engagement can lead to deeper insights and greater community participation in HIV research.
Wistar hosts its 27th Jonathan Lax Memorial Lecture Thursday, June 29th at 5:30 pm EST.
PHILADELPHIA — (June 20, 2023) — When cancer that starts in the body metastasizes to the brain, it is almost always lethal, in part because so few treatment options exist. Now a new study by Wistar scientists published in Nature Communications shows that a type of brain cell called astrocytes plays an important role in promoting brain metastasis by recruiting a specific subpopulation of immune cells.
Wistar is pleased to welcome Sozi Tulante to its Board of Trustees. He is currently General Counsel of Form Energy, a Massachusetts-based energy storage technology and manufacturing company.
Wistar Institute has formed a collaboration with the Pennsylvania Biotechnology Center and the Baruch S. Blumberg Institute to accelerate the advancement of “bench to bedside” biomedical research discoveries in the tri-state region.
Wistar Institute researchers have uncovered a key mechanism as to how p53 suppresses tumors.
Wistar Institute researchers identified hopeaphenol, a natural plant-based compound, as possessing antiviral properties that are effective against HIV.
Wistar scientists have identified a gene signature that accurately predicts the functioning of P53 variants, important information to assessing cancer risk and optimizing choices for cancer therapeutics.
The Cotswold Foundation Postdoctoral Fellowship is a new fellowship totaling $500,000 over the course of five years to support a postdoctoral researcher studying immunology, cancer research, or vaccine biology at The Wistar Institute.
The Wistar Institute, which has recently launched a $75 million programmatic campaign investing in biomedical advances, announces the appointment of Michael Criscuolo as Vice President of Development.
amfAR, The Foundation for AIDS Research, has awarded Luis J. Montaner, D.V.M., D.Phil., in collaboration with Mohamed Abdel-Mohsen, Ph.D., a Target Grant for $397,663 over two years.
Maureen Murphy, Ph.D., has been named Deputy Director of the Ellen and Ronald Caplan Cancer Center at The Wistar Institute. Murphy will guide the growth of the Cancer Center through expanding research initiatives and collaboration, education and training programs, and recruitment to fast-track innovative basic cancer research discoveries into future transformative drugs and therapies.
The Wistar Institute Biomedical Technician Training (BTT) Program was awarded Workforce Champion of the Year in the 3rd Annual 2022 BioBuzz Awards. The program is a collaborative that includes The Wistar Institute, West Philadelphia Skills Initiative, Iovance Biotherapeutics, PIDC, and others.
The Wistar Insitute, William Way Community Center, Philadelphia FIGHT, BEAT-HIV Delaney Collaboratory, Philadelphia Foundation, and The Penn Center for AIDS Research are proud to announce that “The London Patient” Adam Castillejo will take part in a panel conversation and Q&A on Wednesday, October 26 from 5 to 8 pm
In a research paper published in PLOS ONE, The Wistar Institute's Dario C. Altieri, M.D., alongside national and international collaborators, distinguish a specific gene signature indicative of mitochondrial reprogramming in tumors that correlates with poor patient outcome.
The National Institutes of Health has awarded Amelia Escolano, Ph.D., assistant professor in The Wistar Institute’s Vaccine & Immunotherapy Center, the 2022 NIH Director’s New Innovator Award.
Currently, the only FDA approved biomarker for ICI melanoma treatment is the tumor mutation burden assay, but the mechanisms linking it to ICI remain unclear. However, new research out of The Wistar Institute now provides evidence of novel, reliable biomarkers that predict therapy response using advanced computer technology.
The Wistar Institute is pleased to announce the appointment of Michele A. Schiavoni, M.S., as Vice President of Communications & Marketing, in a central leadership role that will bolster the visibility of the Institute’s ambitious biomedical research science initiatives and programs advancing the organization’s newly launched Bold Science // Global Impact Capital Campaign.
Researchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at Jubilant Therapeutics Inc. have uncovered a novel mechanism by which protein arginine deiminase 4 (PAD4) in neutrophils promotes cancer progression. The paper also found that inhibition of this function of PAD4 reduces primary tumor growth and metastasis and enhances checkpoint inhibitor treatments.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right